AB­VC Bio­Phar­ma to break ground in Chi­na, ad­vances 20% stake in Zhonghui re­al es­tate 

Cal­i­for­nia-head­quar­tered AB­VC Bio­Phar­ma is to ex­pand its ge­o­graph­ic reach through an ac­qui­si­tion agree­ment with Zhonghui Unit­ed, with the biotech mov­ing ahead with a 20% own­er­ship stake in Zhonghui’s re­al es­tate in Cheng­du, Chi­na.

The deal is worth ap­prox­i­mate­ly $7.4 mil­lion, which is in the ball­park of 370,000 shares of AB­VC stock at $20 per share, as per AB­VC’s Thurs­day press re­lease.

Ac­cord­ing to an SEC fil­ing, the land and prop­er­ty is in Le­shan, Sichuan, Chi­na. The even­tu­al fa­cil­i­ty is en­vi­sioned as AB­VC’s “base for the Chi­na mar­ket and glob­al de­vel­op­ment.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA